AXL and/or GAS6 overexpression have been reported in multiple human cancers such as glioma [11], melanoma [12], breast [13], lung [14], and ovarian cancer [15], and high level of AXL was associated with increased tumor progression and poorer overall survival [16, 17]. This evidence concerns the gene AXL and central nervous system cancer.